Approved, Compounded, or Neither: How US Law Sorts a Peptide Into Four Different Boxes

A single peptide can occupy any of four distinct legal states, and the habit of collapsing them into one question of "is it legal?" is where most confusion begins. The same molecule may be an FDA-approved drug, a substance a pharmacy is permitted to compound under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, a chemical sold strictly for laboratory research, or an ingredient sitting on an FDA list while the agency decides what to do with it. These are separate categories with separate rules. Knowing which box a peptide sits in tells you almost nothing about the others.

Box one: FDA-approved

An FDA-approved peptide is a finished drug product that a manufacturer studied in clinical trials and that the agency reviewed for safety, efficacy, manufacturing quality, and labeling. Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza) are approved peptide-based drugs, each cleared for specific indications with a defined dose, formulation, and package insert.

Approval is molecule-plus-context. A drug is approved as a specific product for specific uses, not as a free-floating substance. That distinction matters because it is the reason the same peptide can be legal in one form and unlawful in another. Approval attaches to the finished product that went through review, not to the raw ingredient a compounder might buy.

Box two: compounded under 503A or 503B

Compounding is the practice of combining or altering ingredients to create a medication tailored to a patient. US law creates two compounding pathways, and they are not interchangeable.

Section 503A covers traditional pharmacy compounding, typically patient-specific and prescription-driven at a state-licensed pharmacy. Section 503B covers "outsourcing facilities," which register with the FDA, follow current good manufacturing practice, and can produce larger batches without a patient-specific prescription. Each pathway has its own list of bulk drug substances that may be used, and the lists are governed by different statutory standards. A substance permitted for one is not automatically permitted for the other.

The 503B pathway turns on a "clinical need" finding. In a proposal announced on April 30, 2026, the FDA moved to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating that it had not identified a clinical need for outsourcing facilities to compound these drugs from bulk substance. The accompanying Federal Register notice published May 1, 2026, opened a public comment period, and the agency later extended that comment period through a separate notice. This is the sharpest illustration of why the boxes must be kept separate: a peptide that is approved as a finished drug can simultaneously be proposed for exclusion from a compounding list. Approval and compounding eligibility answer different questions, and a proposal is a proposal until the agency issues a final determination.

Box three: research use only

A large volume of peptide material is sold labeled "for research use only," meaning it is intended for laboratory work, not administration to people. Sections 503A and 503B apply to drugs intended for administration to a human being. Material genuinely destined for in vitro assays, instrument calibration, or preclinical animal studies sits outside those provisions.

The critical caveat is that the label describes intended use, not a safety grade. "Research use only" is not a quieter form of approval, and it carries no assurance of the identity, purity, or sterility expected of a medicine. Redirecting a research-labeled chemical toward human use does not inherit any of the protections that attach to an approved or properly compounded product. It abandons them.

Box four: on an FDA bulk-substances list, under evaluation

The fourth box is the one most often mistaken for the others. To be eligible for compounding when no approved product covers the need, a bulk drug substance generally must appear on an FDA list. While the agency evaluates nominated substances, it sorts many into an interim framework. As the FDA's 503A guidance describes, Category 1 substances are those nominated with enough information to evaluate and against which the agency does not intend to take action while review continues, provided the guidance conditions are met. Category 2 substances are those the agency has identified as raising significant safety concerns and that are therefore not eligible for the Category 1 policy.

In 2026 the FDA removed a set of peptides from Category 2 and announced Pharmacy Compounding Advisory Committee (PCAC) meetings, held in July 2026, to consider whether to recommend adding certain peptide bulk substances to the 503A list. It is essential to read this precisely. Removal from a "do not compound" safety-risk category is not approval, is not placement on the permitted Category 1 list, and is not permission to compound. The PCAC is an advisory body; its recommendations are non-binding. Adding a substance to the 503A bulks list requires notice-and-comment rulemaking, a formal process that follows any recommendation. A committee agenda is a proposal to deliberate, nothing more.

Why the boxes get confused

Marketing collapses these states on purpose. Phrases like "FDA-registered facility," "clinical-grade," and "under FDA review" borrow the authority of one box to describe a peptide sitting in another. A registered outsourcing facility is not an approved drug. A substance under evaluation is not an approved substance. A research chemical is not a medicine. The discipline is to ask which specific box applies to this specific molecule in this specific form, and to resist letting a favorable-sounding phrase from one category stand in for the rest.

This piece is educational and not medical advice. The value in separating the four states is not legal trivia. It is that each box represents a different amount of evidence that a given peptide, in a given form, is what it claims to be and does what is claimed. Conflating them quietly discards that evidence, which is precisely what the categories exist to preserve.